What is Wrong with Cardiac Conditioning? We May be Shooting at Moving Targets

Journal of Cardiovascular Pharmacology and Therapeutics

Volumn 20, Issue 4, 2015, Pages 357-369

  Iliodromitis, Efstathios K ^a   Cohen, Michael V ^b   Dagres, Nikolaos ^a   Andreadou, Ioanna ^c   Kremastinos, Dimitrios Th ^a   Downey, James M ^b  

^a IASO GENERAL HOSPITAL   (Greece)

^b UNIVERSITY OF SOUTH ALABAMA COLLEGE OF MEDICINE   (United States)

^c UNIVERSITY OF ATHENS   (Greece)

Author keywords

angioplasty; cardioprotection; myocardial infarction; postconditioning; preconditioning; remote conditioning

Indexed keywords

ADENOSINE; ATRIAL NATRIURETIC FACTOR; CREATINE KINASE; ERYTHROPOIETIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; NICORANDIL;

ACUTE HEART INFARCTION; ANGIOPLASTY; CORONARY ARTERY BLOOD FLOW; DRUG SAFETY; ELECTIVE SURGERY; HEART INFARCTION SIZE; HEART MUSCLE ISCHEMIA; HEART MUSCLE REPERFUSION; HEART PROTECTION; HUMAN; ISCHEMIC POSTCONDITIONING; ISCHEMIC PRECONDITIONING; NONHUMAN; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; REVIEW; THERAPY EFFECT; ANIMAL; CORONARY OCCLUSION; HEART CATHETERIZATION; HEART INFARCTION PREVENTION; MYOCARDIAL INFARCTION; MYOCARDIAL ISCHEMIA; MYOCARDIAL REPERFUSION INJURY; PATHOLOGY; PROCEDURES; SIGNAL TRANSDUCTION;

ANGIOPLASTY; ANIMALS; CARDIAC CATHETERIZATION; CORONARY OCCLUSION; HUMANS; ISCHEMIC POSTCONDITIONING; ISCHEMIC PRECONDITIONING, MYOCARDIAL; MYOCARDIAL INFARCTION; MYOCARDIAL ISCHEMIA; MYOCARDIAL REPERFUSION INJURY; SIGNAL TRANSDUCTION;

EID: 84929213264     PISSN: 10742484     EISSN: 19404034     Source Type: Journal    
DOI: 10.1177/1074248414566459     Document Type: Review

References (102)

1. Yellon DM, Hausenloy DJ. Myocardial reperfusion injury. N Engl J Med. 2007 ; 357 (11). 1121-1135
2. Kloner RA. Current state of clinical translation of cardioprotective agents for acute myocardial infarction. Circ Res. 2013 ; 113 (4). 451-463
3. Maroko PR, Kjekshus JK, Sobel BE, et al. Factors influencing infarct size following experimental coronary artery occlusions. Circulation. 1971 ; 43 (1). 67-82
4. Murry CE, Jennings RB, Reimer KA. Preconditioning with ischemia: a delay of lethal cell injury in ischemic myocardium. Circulation. 1986 ; 74 (5). 1124-1136
5. Van Winkle DM, Thornton JD, Downey DM, Downey JM. The natural history of preconditioning: cardioprotection depends on duration of transient ischemia and time to subsequent ischemia. Coron Artery Dis. 1991 ; 2 (5). 613-619
6. Iliodromitis EK, Kremastinos DT, Katritsis DG, Papadopoulos CC, Hearse DJ. Multiple cycles of preconditioning cause loss of protection in open-chest rabbits. J Mol Cell Cardiol. 1997 ; 29 (3). 915-920
7. Sandhu R, Diaz RJ, Mao GD, Wilson GJ. Ischemic preconditioning. Differences in protection and susceptibility to blockade with single-cycle versus multicycle transient ischemia. Circulation. 1997 ; 96 (3). 984-995
8. Yamashita N, Hoshida S, Taniguchi N, Kuzuya T, Hori M. A "second window of protection" occurs 24 h after ischemic preconditioning in the rat heart. J Mol Cell Cardiol. 1998 ; 30 (6). 1181-1189
9. Pagliaro P, Gattullo D, Rastaldo R, Losano G. Ischemic preconditioning: from the first to the second window of protection. Life Sci. 2001 ; 69 (1). 1-15
10. Andreadou I, Iliodromitis EK, Koufaki M, Kremastinos DT. Pharmacological pre- and post-conditioning agents: reperfusion-injury of the heart revisited. Mini Rev Med Chem. 2008 ; 8 (9). 952-959
11. Andreotti F, Pasceri V, Hackett DR, Davies GJ, Haider AW, Maseri A. Preinfarction angina as a predictor of more rapid coronary thrombolysis in patients with acute myocardial infarction. N Engl J Med. 1996 ; 334 (1). 7-12
12. Ishihara M, Sato H, Tateishi H, et al. Implications of prodromal angina pectoris in anterior wall acute myocardial infarction: acute angiographic findings and long-term prognosis. J Am Coll Cardiol. 1997 ; 30 (4). 970-975
13. Kloner RA, Shook T, Antman EM, et al. Prospective temporal analysis of the onset of preinfarction angina versus outcome: an ancillary study in TIMI-9B. Circulation. 1998 ; 97 (11). 1042-1045
14. Pêgo-Fernandes PM, Jatene FB, Kwasnicka K, et al. Ischemic preconditioning in myocardial revascularization with intermittent aortic cross-clamping. J Card Surg. 2000 ; 15 (5). 333-338
15. Gheeraert PJ, Henriques JPS, De Buyzere ML, De Pauw M, Taeymans Y, Zijlstra F. Preinfarction angina protects against out-of-hospital ventricular fibrillation in patients with acute occlusion of the left coronary artery. J Am Coll Cardiol. 2001 ; 38 (5). 1369-1374
16. Zhao Z-Q, Corvera JS, Halkos ME, et al. Inhibition of myocardial injury by ischemic postconditioning during reperfusion: comparison with ischemic preconditioning. Am J Physiol. 2003 ; 285 (2). H579 - H588
17. Staat P, Rioufol G, Piot C, et al. Postconditioning the human heart. Circulation. 2005 ; 112 (14). 2143-2148
18. Okamoto F, Allen BS, Buckberg GD, Bugyi H, Leaf J. Reperfusion conditions: importance of ensuring gentle versus sudden reperfusion during relief of coronary occlusion. J Thorac Cardiovasc Surg. 1986 ; 92 (3). 613-620
19. Na HS, Kim YI, Yoon YW, Han HC, Nahm SH, Hong SK. Ventricular premature beat-driven intermittent restoration of coronary blood flow reduces the incidence of reperfusion-induced ventricular fibrillation in a cat model of regional ischemia. Am Heart J. 1996 ; 132 (1). 78-83
20. Schulz R, Cohen MV, Behrends M, Downey JM, Heusch G. Signal transduction of ischemic preconditioning. Cardiovasc Res. 2001 ; 52 (2). 181-198
21. Hausenloy DJ, Yellon DM. New directions for protecting the heart against ischaemia-reperfusion injury: targeting the Reperfusion Injury Salvage Kinase (RISK)-pathway. Cardiovasc Res. 2004 ; 61 (3). 448-460
22. Cohen MV, Downey JM. Signalling pathways and mechanisms of protection in pre- and postconditioning: historical perspective and lessons for the future [published online September 10, 2014]. Br J Pharmacol. 2015 ;:
23. Hausenloy DJ, Boston-Griffiths EA, Yellon DM. Cyclosporin A and cardioprotection: from investigative tool to therapeutic agent. Br J Pharmacol. 2012 ; 165 (5). 1235-1245
24. Przyklenk K, Bauer B, Ovize M, Kloner RA, Whittaker P. Regional ischemic 'preconditioning' protects remote virgin myocardium from subsequent sustained coronary occlusion. Circulation. 1993 ; 87 (3). 893-899
25. Steensrud T, Li J, Dai X, et al. Pretreatment with the nitric oxide donor SNAP or nerve transection blocks humoral preconditioning by remote limb ischemia or intra-arterial adenosine. Am J Physiol. 2010 ; 299 (5). H1598 - H1603
26. Gross ER, Hsu AK, Urban TJ, Mochly-Rosen D, Gross GJ. Nociceptive-induced myocardial remote conditioning is mediated by neuronal gamma protein kinase C. Basic Res Cardiol. 2013 ; 108 (5). 381
27. Tota B, Quintieri AM, Angelone T. The emerging role of nitrite as an endogenous modulator and therapeutic agent of cardiovascular function. Curr Med Chem. 2010 ; 17 (18). 1915-1925
28. Takahashi M. Role of the SDF-1/CXCR4 system in myocardial infarction. Circ J. 2010 ; 74 (3). 418-423
29. Heusch G, Schulz R. Remote preconditioning. J Mol Cell Cardiol. 2002 ; 34 (10). 1279-1281
30. Lim SY, Yellon DM, Hausenloy DJ. The neural and humoral pathways in remote limb ischemic preconditioning. Basic Res Cardiol. 2010 ; 105 (5). 651-655
31. Przyklenk K, Whittaker P. Remote ischemic preconditioning: current knowledge, unresolved questions, and future priorities. J Cardiovasc Pharmacol Ther. 2011 ; 16 (3-4). 255-259
32. Saxena P, Newman MAJ, Shehatha JS, Redington AN, Konstantinov IE. Remote ischemic conditioning: evolution of the concept, mechanisms, and clinical application. J Card Surg. 2010 ; 25 (1). 127-134
33. Heusch G. Reduction of infarct size by ischaemic post-conditioning in humans: fact or fiction?. Eur Heart J. 2012 ; 33 (1). 13-15
34. Edwards RJ, Redwood SR, Lambiase PD, Tomset E, Rakhit RD, Marber MS. Antiarrhythmic and anti-ischaemic effects of angina in patients with and without coronary collaterals. Heart. 2002 ; 88 (6). 604-610
35. Kobayashi H, Miura T, Ishida H, et al. Limitation of infarct size by erythropoietin is associated with translocation of Akt to the mitochondria after reperfusion. Clin Exp Pharmacol Physiol. 2008 ; 35 (7). 812-819
36. Lu R, Hu C-P, Peng J, Deng H-W, Li Y-J. Role of calcitonin gene-related peptide in ischaemic preconditioning in diabetic rat hearts. Clin Exp Pharmacol Physiol. 2001 ; 28 (5-6). 392-396
37. Shi-ting W, Mang-hua X, Wen-ting C, Feng-hou G, Zhu-ying G. Study on tolerance to ischemia-reperfusion injury and protection of ischemic preconditioning of type I diabetes rat heart. Biomed Aging Path. 2011 ; 1 (1). 56-60
38. Ebrahim Z, Yellon DM, Baxter GF. Ischemic preconditioning is lost in aging hypertensive rat heart: independent effects of aging and longstanding hypertension. Exp Gerontol. 2007 ; 42 (8). 807-814
39. Sörensson P, Saleh N, Bouvier F, et al. Effect of postconditioning on infarct size in patients with ST elevation myocardial infarction. Heart. 2010 ; 96 (21). 1710-1715
40. Freixa X, Bellera N, Ortiz-Pérez JT, et al. Ischaemic postconditioning revisited: lack of effects on infarct size following primary percutaneous coronary intervention. Eur Heart J. 2012 ; 33 (1). 103-112
41. Hahn J-Y, Song YB, Kim EK, et al. Ischemic postconditioning during primary percutaneous coronary intervention: the effects of postconditioning on myocardial reperfusion in patients with ST-segment elevation myocardial infarction (POST) random-ized trial. Circulation. 2013 ; 128 (17). 1889-1896
42. Limalanathan S, Andersen GØ, Kløw N-E, Abdelnoor M, Hoffmann P, Eritsland J. Effect of ischemic postconditioning on infarct size in patients with ST-elevation myocardial infarction treated by primary PCI: results of the POSTEMI (POstconditioning in ST-Elevation Myocardial Infarction) randomized trial. J Am Heart Assoc. 2014 ; 3 (2). e000679
43. Favaretto E, Roffi M, Frigo AC, et al. Meta-analysis of random-ized trials of postconditioning in ST-elevation myocardial infarction. Am J Cardiol. 2014 ; 114 (6). 946-952
44. Cohen MV, Yang X-M, Downey JM. The pH hypothesis of postconditioning: staccato reperfusion reintroduces oxygen and perpetuates myocardial acidosis. Circulation. 2007 ; 115 (14). 1895-1903
45. Nicolli A, Petronilli V, Bernardi P. Modulation of the mitochondrial cyclosporin A-sensitive permeability transition pore by matrix pH. Evidence that the pore open-closed probability is regulated by reversible histidine protonation. Biochemistry. 1993 ; 32 (16). 4461-4465
46. Yang X-M, Proctor JB, Cui L, Krieg T, Downey JM, Cohen MV. Multiple, brief coronary occlusions during early reperfusion protect rabbit hearts by targeting cell signaling pathways. J Am Coll Cardiol. 2004 ; 44 (5). 1103-1110
47. Patti G, Bárczi G, Orlic D, et al. Outcome comparison of 600- and 300-mg loading doses of clopidogrel in patients undergoing primary percutaneous coronary intervention for ST-segment elevation myocardial infarction: results from the ARMYDA-6 MI (Antiplatelet therapy for Reduction of MYocardial Damage during Angioplasty-Myocardial Infarction) randomized study. J Am Coll Cardiol. 2011 ; 58 (15). 1592-1599
48. Yang X-M, Cui L, Alhammouri A, Downey JM, Cohen MV. Triple therapy greatly increases myocardial salvage during ischemia/reperfusion in the in situ rat heart. Cardiovasc Drugs Ther. 2013 ; 27 (5). 403-412
49. Yang X-M, Liu Y, Cui L, et al. Platelet P2Y12 blockers confer direct postconditioning-like protection in reperfused rabbit hearts. J Cardiovasc Pharmacol Ther. 2013 ; 18 (3). 251-262
50. Cohen MV, Downey JM. Combined cardioprotectant and antithrombotic actions of platelet P2Y12 receptor antagonists in acute coronary syndrome: just what the doctor ordered. J Cardiovasc Pharmacol Ther. 2014 ; 19 (2). 179-190
51. Roubille F, Lairez O, Mewton N, et al. Cardioprotection by clopidogrel in acute ST-elevated myocardial infarction patients: a retrospective analysis. Basic Res Cardiol. 2012 ; 107 (4). 275
52. Mochly-Rosen D, Grimes KV. Myocardial salvage in acute myocardial infarction-challenges in clinical translation. J Mol Cell Cardiol. 2011 ; 51 (4). 451-453
53. Bøtker HE, Kharbanda R, Schmidt MR, et al. Remote ischaemic conditioning before hospital admission, as a complement to angioplasty, and effect on myocardial salvage in patients with acute myocardial infarction: a randomised trial. Lancet. 2010 ; 375 (9716). 727-734
54. Crimi G, Pica S, Raineri C, et al. Remote ischemic post-conditioning of the lower limb during primary percutaneous coronary intervention safely reduces enzymatic infarct size in anterior myocardial infarction. A randomized controlled trial. JACC Cardiovasc Interv. 2013 ; 6 (10). 1055-1063
55. Prunier F, Angoulvant D, Saint Etienne C, et al. The RIPOST-MI study, assessing remote ischemic perconditioning alone or in combination with local ischemic postconditioning in ST-segment elevation myocardial infarction. Basic Res Cardiol. 2014 ; 109 (2). 400
56. Xin P, Zhu W, Li J, et al. Combined local ischemic postconditioning and remote perconditioning recapitulate cardioprotective effects of local ischemic preconditioning. Am J Physiol. 2010 ; 298 (6). H1819 - H1831
57. Sachdeva J, Dai W, Gerczuk PZ, Kloner RA. Combined remote perconditioning and postconditioning failed to attenuate infarct size and contractile dysfunction in a rat model of coronary artery occlusion. J Cardiovasc Pharmacol Ther. 2014 ; 19 (6). 567-573
58. Mahaffey KW, Puma JA, Barbagelata NA, et al. Adenosine as an adjunct to thrombolytic therapy for acute myocardial infarction. Results of a multicenter, randomized, placebo-controlled trial: the Acute Myocardial Infarction STudy of ADenosine (AMISTAD) trial. J Am Coll Cardiol. 1999 ; 34 (6). 1711-1720
59. Ross AM, Gibbons RJ, Stone GW, Kloner RA, Alexander RW. A randomized, double-blinded, placebo-controlled multicenter trial of adenosine as an adjunct to reperfusion in the treatment of acute myocardial infarction (AMISTAD-II). J Am Coll Cardiol. 2005 ; 45 (11). 1775-1780
60. Kloner RA, Forman MB, Gibbons RJ, Ross AM, Alexander RW, Stone GW. Impact of time to therapy and reperfusion modality on the efficacy of adenosine in acute myocardial infarction: the AMISTAD-2 trial. Eur Heart J. 2006 ; 27 (20). 2400-2405
61. Marzilli M, Orsini E, Marraccini P, Testa R. Beneficial effects of intracoronary adenosine as an adjunct to primary angioplasty in acute myocardial infarction. Circulation. 2000 ; 101 (18). 2154-2159
62. Fokkema ML, Vlaar PJ, Vogelzang M, et al. Effect of high-dose intracoronary adenosine administration during primary percutaneous coronary intervention in acute myocardial infarction: a randomized controlled trial. Circ Cardiovasc Interv. 2009 ; 2 (4). 323-329
63. Desmet W, Bogaert J, Dubois C, et al. High-dose intracoronary adenosine for myocardial salvage in patients with acute ST-segment elevation myocardial infarction. Eur Heart J. 2011 ; 32 (7). 867-877
64. Mewton N, Croisille P, Gahide G, et al. Effect of cyclosporine on left ventricular remodeling after reperfused myocardial infarction. J Am Coll Cardiol. 2010 ; 55 (12). 1200-1205
65. Yang X-M, Philipp S, Downey JM, Cohen MV. Atrial natriuretic peptide administered just prior to reperfusion limits infarction in rabbit hearts. Basic Res Cardiol. 2006 ; 101 (4). 311-318
66. Ott I, Schulz S, Mehilli J, et al. Erythropoietin in patients with acute ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention: a randomized, double-blind trial. Circ Cardiovasc Interv. 2010 ; 3 (5). 408-413
67. Najjar SS, Rao SV, Melloni C, et al. Intravenous erythropoietin in patients with ST-segment elevation myocardial infarction. REVEAL: a randomized controlled trial. JAMA. 2011 ; 305 (18). 1863-1872
68. Kitakaze M, Asakura M, Kim J, et al. Human atrial natriuretic peptide and nicorandil as adjuncts to reperfusion treatment for acute myocardial infarction (J-WIND): two randomised trials. Lancet. 2007 ; 370 (9597). 1483-1493
69. Ludman A, Venugopal V, Yellon DM, Hausenloy DJ. Statins and cardioprotection - more than just lipid lowering?. Pharmacol Ther. 2009 ; 122 (1). 30-43
70. Laufs U, La Fata V, Liao JK. Inhibition of 3-hydroxy-3-methylglutaryl (HMG)-CoA reductase blocks hypoxia-mediated down-regulation of endothelial nitric oxide synthase. J Biol Chem. 1997 ; 272 (50). 31725-31729
71. Bell RM, Yellon DM. Atorvastatin, administered at the onset of reperfusion, and independent of lipid lowering, protects the myocardium by up-regulating a pro-survival pathway. J Am Coll Cardiol. 2003 ; 41 (3). 508-515
72. Ko Y-G, Won H, Shin D-H, et al. Efficacy of early intensive rosuvastatin therapy in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention (ROSEMARY study). Am J Cardiol. 2014 ; 114 (1). 29-35
73. Kim J-S, Kim J, Choi D, et al. Efficacy of high-dose atorvastatin loading before primary percutaneous coronary intervention in ST-segment elevation myocardial infarction: the STATIN STEMI trial. JACC Cardiovasc Interv. 2010 ; 3 (3). 332-339
74. Pitarys CJ, Virmani R, Vildibill HD, Jackson EK, Forman MB. Reduction of myocardial reperfusion injury by intravenous adenosine administered during the early reperfusion period. Circulation. 1991 ; 83 (1). 237-247
75. Vander Heide RS, Reimer KA. Effect of adenosine therapy at reperfusion on myocardial infarct size in dogs. Cardiovasc Res. 1996 ; 31 (5). 711-718
76. Lim SY, Davidson SM, Hausenloy DJ, Yellon DM. Preconditioning and postconditioning: the essential role of the mitochondrial permeability transition pore. Cardiovasc Res. 2007 ; 75 (3). 530-535
77. Piot C, Croisille P, Staat P, et al. Effect of cyclosporine on reperfusion injury in acute myocardial infarction. N Engl J Med. 2008 ; 359 (5). 473-481
78. Iliodromitis EK, Paraskevaidis IA, Fountoulaki K, et al. Staccato reperfusion prevents reperfusion injury in patients undergoing coronary angioplasty: a 1-year follow-up pilot study. Atherosclerosis. 2009 ; 204 (2). 497-502
79. Ikonomidis I, Iliodromitis EK, Tzortzis S, et al. Staccato reperfusion improves myocardial microcirculatory function and long-term left ventricular remodelling: a randomised contrast echocardiography study. Heart. 2010 ; 96 (23). 1898-1903
80. Hoole SP, Heck PM, Sharples L, et al. Cardiac remote ischemic preconditioning in coronary stenting (CRISP Stent) study: a prospective, randomized control trial. Circulation. 2009 ; 119 (6). 820-827
81. Davies WR, Brown AJ, Watson W, et al. Remote ischemic preconditioning improves outcome at 6 years after elective percutaneous coronary intervention: the CRISP Stent trial long-term follow-up. Circ Cardiovasc Interv. 2013 ; 6 (3). 246-251
82. Iliodromitis EK, Kyrzopoulos S, Paraskevaidis IA, et al. Increased C reactive protein and cardiac enzyme levels after coronary stent implantation. Is there protection by remote ischaemic preconditioning?. Heart. 2006 ; 92 (12). 1821-1826
83. Carrasco-Chinchilla F, Muñoz-García AJ, Domínguez-Franco A, et al. Remote ischaemic postconditioning: does it protect against ischaemic damage in percutaneous coronary revascularisation? Randomised placebo-controlled clinical trial. Heart. 2013 ; 99 (19). 1431-1437
84. Lavi S, D'Alfonso S, Diamantouros P, et al. Remote ischemic postconditioning during percutaneous coronary interventions: remote ischemic postconditioning-percutaneous coronary intervention randomized trial. Circ Cardiovasc Interv. 2014 ; 7 (2). 225-232
85. Kim S-J, Kim W, Woo J-S, et al. Effect of myocardial protection of intracoronary adenosine and nicorandil injection in patients undergoing non-urgent percutaneous coronary intervention: a randomized controlled trial. Int J Cardiol. 2012 ; 158 (1). 88-92
86. Paraskevaidis IA, Iliodromitis EK, Ikonomidis I, et al. The effect of acute administration of statins on coronary microcirculation during the pre-revascularization period in patients with myocardial infraction. Atherosclerosis. 2012 ; 223 (1). 184-189
87. Solenkova NV, Solodushko V, Cohen MV, Downey JM. Endogenous adenosine protects preconditioned heart during early minutes of reperfusion by activating Akt. Am J Physiol. 2006 ; 290 (1). H441 - H449
88. Liu GS, Thornton J, Van Winkle DM, Stanley AWH, Olsson RA, Downey JM. Protection against infarction afforded by preconditioning is mediated by A1 adenosine receptors in rabbit heart. Circulation. 1991 ; 84 (1). 350-356
89. Pain T, Yang X-M, Critz SD, et al. Opening of mitochondrial KATP channels triggers the preconditioned state by generating free radicals. Circ Res. 2000 ; 87 (6). 460-466
90. Iliodromitis EK, Cokkinos P, Zoga A, Steliou I, Vrettou AR, Kremastinos DT. Oral nicorandil recaptures the waned protection from preconditioning in vivo. Br J Pharmacol. 2003 ; 138 (6). 1101-1106
91. Iliodromitis EK, Andreadou I, Prokovas E, et al. Simvastatin in contrast to postconditioning reduces infarct size in hyperlipid-emic rabbits: possible role of oxidative/nitrosative stress attenuation. Basic Res Cardiol. 2010 ; 105 (2). 193-203
92. Andreadou I, Farmakis D, Prokovas E, et al. Short-term statin administration in hypercholesterolaemic rabbits resistant to postconditioning: effects on infarct size, endothelial nitric oxide synthase, and nitro-oxidative stress. Cardiovasc Res. 2012 ; 94 (3). 501-509
93. Skyschally A, van Caster P, Iliodromitis EK, Schulz R, Kremastinos DT, Heusch G. Ischemic postconditioning: experimental models and protocol algorithms. Basic Res Cardiol. 2009 ; 104 (5). 469-483
94. Lønborg J, Holmvang L, Kelbæk H, et al. ST-Segment resolution and clinical outcome with ischemic postconditioning and comparison to magnetic resonance. Am Heart J. 2010 ; 160 (6). 1085-1091
95. Er F, Nia AM, Dopp H, et al. Ischemic preconditioning for prevention of contrast medium-induced nephropathy: randomized pilot RenPro trial (Renal Protection trial). Circulation. 2012 ; 126 (3). 296-303
96. Healy DA, Khan WA, Wong CS, et al. Remote preconditioning and major clinical complications following adult cardiovascular surgery: systematic review and meta-analysis. Int J Cardiol. 2014 ; 176 (1). 20-31
97. Hausenloy DJ, Candilio L, Laing C, et al. Effect of remote ischemic preconditioning on clinical outcomes in patients undergoing coronary artery bypass graft surgery (ERICCA): rationale and study design of a multi-centre randomized double-blinded controlled clinical trial. Clin Res Cardiol. 2012 ; 101 (5). 339-348
98. Meybohm P, Zacharowski K, Cremer J, et al. Remote ischaemic preconditioning for heart surgery. The study design for a multi-center randomized double-blinded controlled clinical trial - the RIPHeart-Study. Eur Heart J. 2012 ; 33 (12). 1423-1425a
99. Yang X-M, Cui L, White J, et al. Mitochondrially targeted endonuclease III has a powerful anti-infarct effect in an in vivo rat model of myocardial ischemia/reperfusion. Basic Res Cardiol. 2015 ;:
100. Abdelnoor M, Sandven I, Limalanathan S, Eritsland J. Postconditioning in ST-elevation myocardial infarction: a systematic review, critical appraisal, and meta-analysis of randomized clinical trials. Vasc Health Risk Manag. 2014 ; 10: 477-491
101. Schevchuck A, Laskey WK. Ischemic conditioning as an adjunct to percutaneous coronary intervention. Circ Cardiovasc Interv. 2013 ; 6 (4). 484-492
102. Chung S-C, Gedeborg R, Nicholas O, et al. Acute myocardial infarction: a comparison of short-term survival in national outcome registries in Sweden and the UK. Lancet. 2014 ; 383 (9925). 1305-1312